Abstract and Introduction
Topical retinoids are recommended as first line therapy for the treatment of acne. Despite this recommendation, topical retinoids are underutilized, in part because of their tendency to cause cutaneous irritation. Tazarotene 0.045% lotion was developed using polymeric emulsion technology to provide an effective, well tolerated topical retinoid for the treatment of acne.
Acne is a common chronic inflammatory disease of the pilosebaceous unit. Although its prevalence is highest in adolescence, acne often persists into adulthood, especially in women. In fact, more than 50% of women in their 20s and more than 35% in their 30s experience acne. As long-term treatment is frequently required, topical therapy plays a pivotal role in its management. Topical retinoids are recommended as first line therapy for most acne patients by evidence-based guidelines in the US, Europe and Canada.[2–4] Although utilization of retinoids has increased over time, a claims-based study of data obtained from a large US database indicated that of all patients seen by a dermatologist for acne, only 59% were prescribed either an oral or topical retinoid. Nondermatologist physicians prescribed a retinoid to 32% of acne patients. Novel retinoid formulations may improve tolerability and increase use.
Skin Therapy Letter. 2022;27(4):1-3. © 2022 SkinCareGuide.com